Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more about PERSIST-1 here.
PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape
Recent Articles
January 2021 Annual Meeting Edition
This issue features highlights from the 2020 ASH Annual Meeting, a look at patient holiday gift customs around the world, and more.
FDA Approves Ponatinib for Chronic-Phase CML
The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for ponatinib to treat adults with chronic-phase chronic myeloid leukemia...
Large Meta-Analysis Confirms Predictive Value of MRD Negativity in Myeloma
Achievement of measurable residual disease (MRD) negativity is associated with significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with multiple...
Selinexor Combination Approved for Patients with Multiple Myeloma
The FDA has approved selinexor in combination with bortezomib and dexamethasone (Vd) for the treatment of adults with multiple myeloma (MM) who have received...
Big Ideas on Burnout: Trainees Propose System-Wide Solutions
The Special Symposium on Quality at the 2020 ASH Annual Meeting tackled an often-overlooked driver of quality of patient care: burnout. Physician burnout –...
Current Issue
January 2021 Annual Meeting Edition
This issue features highlights from the 2020 ASH Annual Meeting, a look at patient holiday gift customs around the world, and more.